| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology |
Recent Updates
Recently added Catalysts
Treace Medical Concepts, Inc.$4.32
-0.34 (-7.3%)
F 14Pipeline Score MedTech · Commercial
Market Cap
180.35 M
EPS
-0.96
P/E Ratio
-
Value Trade
2.06 M
SEC Financials
Q1 2026Dilution Risk
Revenue
47.20 M
R&D Expenses
4.62 M
Operating CF
7.24 M
Total Assets
184.10 M
Total Liabilities
106.91 M
Equity
77.19 M
D/E Ratio
12,345
-3.47 %
Week
50.27 %
1 Month
45.55 %
3 Month
7.75 %
6 Month
-90.68 %
5 Year
-88.65 %
All Time
Cash Data
Cash Position
51.85 M
Monthly Burn
-
Runway
12,345 mo
Burn Trend
SEC Filing
May 8, 2026
Overview
Volume
431.32 K
52 Week Range
1.17 - 7.78
% held by Insiders
25.85 %
% held by Institutions
56.19 %
Enterprise Value
200.10 M
Total Shares
64.78 M
Short %
3.67 %
Float Shares
47.61 M
Company Description
locked
Upcoming Catalyst
Drug Pipeline Intelligence
F14
Pipeline Score -
Pipeline ValueValuation Signal
0
Drugs Scored—
rNPV / MCap Top 10%
Micro Cap (rank 822 of 912)
Percentile RankTreace Medical Concepts, Inc. has significant pipeline risk (14/100).
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | The study met its primary endpoint demonstrating statistically significant improvement. Read More | Phase 3 Study Results Announcement | |
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | The study met its primary endpoint demonstrating statistically significant improvement. Read More | Phase 3 Study Results Announcement | |
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | The study met its primary endpoint demonstrating statistically significant improvement. Read More | Phase 3 Study Results Announcement |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in TMCI
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
TMCI Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
| 2026-08-21 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2026-08-21 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2026-08-21 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
TMCITreace Medical Concepts Reports First Quarter 2026 Financial Results PONTE VEDRA, Fla. –
Treace Medical Concepts, Inc. reported its financial results for the first quarter of 2026, showcasing a revenue of $47.2 million, a 10% decrease from the previous year. The company experienced a net loss of $(18.0) million and an adjusted EBITDA loss of $(5.5) million. Despite these challenges, Treace announced a limited market release of its new product and a notable increase in its cash reserves. The company reaffirms its full-year revenue outlook but acknowledges ongoing market headwinds affecting pricing and demand.
Read more →TMCI▼ -11.4%on this news· ran to -30% by day 3
Treace Medical Concepts Reports Fourth Quarter and Full-Year 2025 Financial Results PONTE VEDRA, Fla. –
Treace Medical Concepts, Inc. has reported its financial results for Q4 and the full year of 2025, showing a revenue increase of 2% compared to 2024. Despite the growth in revenue, the company experienced a net loss of $(59.0) million for the year, an increase from the previous year’s loss. The company also announced projected revenue guidance for 2026, suggesting a possible decline. Notably, Treace has reduced cash usage significantly and increased its active surgeon base, indicating a proactive approach to operational challenges.
Read more →TMCITreace Announces Preliminary, Unaudited Fourth Quarter and Full-Year 2025 Revenue
Treace Medical Concepts, Inc. has released preliminary unaudited revenue figures for Q4 and full-year 2025, indicating a 2% increase in annual revenue but a 9% decline in Q4 revenue compared to the previous year. The company added approximately 202 active surgeons, reaching a total of about 3,337, and noted growth in procedure volumes driven by new 3D bunion technologies. However, Treace acknowledges ongoing challenges related to economic conditions and consumer sentiment, and has not provided guidance for 2026 at this time.
Read more →TMCITreace Medical Secures Up to $175 Million in Debt Financing New 5-Year Agreement Provides Continued Financial Strength & Flexibility
Treace Medical Concepts, Inc. has announced a new five-year $175 million senior secured loan arrangement with SLR Capital Partners. This financing includes $60 million in immediate term loans and further availability up to $65 million, along with a $50 million revolving credit facility. The funds will be used to prepay existing loans, reinforcing Treace's financial position and providing liquidity for future growth in the bunion surgery market. CEO John T. Treace emphasized that this financing enhances the company's competitive position and helps advance its commercial strategies.
Read more →TMCITreace Medical Concepts Reports Third Quarter 2025 Financial Results PONTE VEDRA, Fla. –
Treace Medical Concepts reported its financial results for Q3 2025, revealing an 11% increase in revenue, totaling $50.2 million. The company also noted a net loss of $(16.3) million, though adjusted EBITDA improved significantly. Treace expanded its product offerings and patent portfolio, but has revised its full-year revenue guidance downwards due to expected lower sales of its flagship products and prevailing market conditions. Macroeconomic challenges and shifts in patient preferences have influenced these outcomes.
Read more →TMCITreace Medical Concepts Reports Second Quarter 2025 Financial Results Announces Full Market Release of Three New Bunion Technologies PONTE VEDRA, Fla. –
Treace Medical Concepts, Inc. reported its second quarter 2025 financial results, achieving a revenue of $47.4 million, which is a 7% growth from the previous year. The net loss was reduced by 18%, and the company improved its adjusted EBITDA by 58%. Treace also announced the full market release of three new bunion technology systems, which adds to its existing portfolio. Overall, the financial outlook for 2025 remains optimistic, with a revenue guidance of $224 million to $230 million.
Read more →TMCITreace Medical Concepts Reports First Quarter 2025 Financial Results PONTE VEDRA, Fla. –
Treace Medical Concepts, Inc. reported its financial results for the first quarter of 2025, indicating a revenue increase of 3% year-over-year. The company improved its net loss by 15% and achieved a notable improvement in adjusted EBITDA. Treace also expanded its product portfolio with new bunion systems and presented positive clinical data at a recent conference. Looking forward, the company is reaffirming its revenue guidance of $224 million to $230 million for the full year 2025.
Read more →TMCITreace Announces Upcoming Board Chair Transition
Treace Medical Concepts, Inc. announced a leadership transition with John T. Treace appointed as Chairman of the Board, effective after the 2025 Annual Meeting. He will succeed James T. Treace, who is retiring after years of service. The board's decision signifies a strategic shift as they aim to enhance innovations in the bunion treatment market. John T. Treace's experience as CEO is expected to support the company's growth objectives going forward.
Read more →TMCI▼ -5.9%on this news
Treace Medical Concepts Reports Fourth Quarter and Full-Year 2024 Financial Results PONTE VEDRA, Fla. –
Treace Medical Concepts reported its financial results for Q4 and full-year 2024, showcasing a 10% revenue increase to $68.7 million for the fourth quarter and a 12% increase for the full year to $209.4 million. The company significantly improved its adjusted EBITDA by 322%, reaching $11.1 million in Q4. However, there was an increase in net loss for the year, indicating ongoing challenges. Looking ahead, Treace is optimistic with a revenue guidance for 2025 that expects a growth of 7% to 10% compared to 2024.
Read more →TMCI▲ +14.5%on this news
Treace Announces Preliminary, Unaudited Fourth Quarter and Full-Year 2024 Revenue
Treace Medical Concepts, Inc. announced its preliminary, unaudited revenue results for the fourth quarter and full year of 2024. The company reported a revenue increase of approximately 10% in Q4 and a 12% increase for the full year compared to 2023, aligning with previous guidance. Treace also noted an addition of 280 active surgeons, marking a significant rise in its user base. The company is optimistic about entering 2025 with new product launches aimed at further penetrating the bunion market.
Read more →TMCI▲ +6.1%on this news· ran to +48% by day 3
Treace Medical Concepts Reports Third Quarter 2024 Financial Results PONTE VEDRA, Fla. –
Treace Medical Concepts, Inc. reported its financial results for the third quarter of 2024, revealing a revenue increase of 11% year-over-year to $45.1 million. The company noted an improved net loss of ($15.4) million, down from ($17.5) million in the prior year, alongside a significant reduction in adjusted EBITDA loss. Treace announced the launch of its Nanoplasty 3D procedure as its entry into the osteotomy market, with plans for further technological expansions. Despite rising operating expenses, Treace believes it has the financial strength to pursue strategic investments and growth initiatives.
Read more →TMCITreace Files Patent Infringement and Unfair Competition Suit to Protect Lapiplasty Bunion Technology
Treace Medical Concepts, Inc. has initiated a patent infringement and unfair competition lawsuit against Stryker Corporation and its subsidiary for allegedly infringing on nine patents related to their Lapiplasty 3D Bunion Correction technologies. This legal action, filed in the U.S. District Court for New Jersey, seeks damages and injunctive relief. Treace aims to protect its pioneering innovations and reassure investors of its commitment to intellectual property rights amidst growing competition. The company anticipates significant financial improvements in the coming years, projecting a 50% increase in Adjusted EBITDA in 2024 and breakeven by 2025.
Read more →TMCI▲ +5.2%on this news
Treace Medical Concepts Reports Second Quarter 2024 Financial Results PONTE VEDRA, Fla. –
Treace Medical Concepts, Inc. reported its financial results for the second quarter of 2024, demonstrating a revenue rise of 6% to $44.5 million compared to the same period in 2023. The gross margin stood at a notable 80.2%, although the company faced increasing operating expenses totaling $57.1 million. A significant net loss of $21.2 million was reported, indicating challenges in profitability, despite a positive outlook corroborated by continued product innovation and a reaffirmation of its full-year revenue guidance.
Read more →TMCITreace Medical Concepts Reports First Quarter 2024 Financial Results PONTE VEDRA, Fla. –
Treace Medical Concepts reported its financial results for Q1 2024, showing a revenue increase of 21% year-over-year to $51.1 million. Despite this growth, the company faced a net loss of $18.7 million, which is higher than the previous year's loss. They also revised their revenue guidance for the full year downward, citing competition and market changes. The company continues to innovate with new technologies and aims to improve its adjusted EBITDA in the coming months.
Read more →TMCITreace Medical Concepts Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides 2024 Guidance PONTE VEDRA, Fla. –
Treace Medical Concepts reported substantial financial growth for Q4 and full-year 2023, with revenues rising by 25% in the fourth quarter and 32% for the full year. The company attributes this growth to an expanding customer base and increased utilization of its Lapiplasty procedure kits. Despite these gains, Treace also faced challenges with operating expenses and increased net losses. For 2024, Treace anticipates continued growth, expecting revenues between $220 million and $225 million.
Read more →TMCI▲ +6.6%on this news
nd Annual J.P. Morgan Healthcare Conference John T. Treace, CEO & Founder
At the 42nd Annual J.P. Morgan Healthcare Conference, Treace Medical Concepts, Inc. (TMCI) presented its initiatives and financial outlook. The company projects a 32% year-over-year revenue growth for FY 2023, reaching between $186.7 million and $187.1 million. TMCI aims for adjusted EBITDA breakeven in FY 2024 and cash flow positive status by 2025, bolstered by 10 new product launches planned in the near term. Additionally, TMCI emphasizes its strong liquidity position, reducing concerns regarding future equity financing.
Read more →TMCI▲ +6.6%on this news
Treace Announces Preliminary, Unaudited Fourth Quarter and Full-Year 2023 Revenue Company to Present at J.P. Morgan Healthcare Conference on Tuesday
Treace Medical Concepts, Inc. has announced preliminary unaudited revenue results for Q4 and full-year 2023, highlighting significant growth in financial performance. The company reported a Q4 revenue of $61.8 million to $62.2 million, marking an increase of approximately 25% year-over-year. For the full year, revenue reached between $186.7 million and $187.1 million, exceeding prior guidance and reflecting a 32% growth compared to 2022. Additionally, Treace plans to provide financial guidance for 2024 during its upcoming earnings call on February 27, 2024.
Read more →TMCI▼ -6.7%on this news· ran to -42% by day 1
Treace Medical Concepts Reports Third Quarter 2023 Financial Results PONTE VEDRA, Fla. –
Treace Medical Concepts reported a strong third quarter in 2023 with $40.8 million in revenue, reflecting a 23% increase year-over-year. The blended average revenue per procedure kit sold reached a record high, largely due to the introduction of new technologies. However, the company reported a net loss of $17.5 million and increased operating expenses, necessitating a revision of its full-year revenue forecast downwards. Despite these challenges, Treace's CEO expressed confidence in the company's growth strategy and performance metrics.
Read more →TMCITreace Medical Concepts Reports Second Quarter 2023 Financial Results PONTE VEDRA, Fla. –
Treace Medical Concepts reported a strong 40% increase in revenue for the second quarter of 2023, reaching $42.0 million. The company also expanded its gross margin to 81.7% and exceeded its target by increasing its direct sales representatives. However, operating expenses rose substantially to $47.3 million, and the company reported a net loss of $12.3 million. On a positive note, Treace raised its full-year revenue guidance, indicating continued growth expectations.
Read more →TMCIJUNE 1, 2023 Forward Looking Statements and Other Cautions This presentation may include forward- looking statements. All statements other than statements of historical facts contained in this presentation, including sta
The presentation includes forward-looking statements about the company's future operations, strategies, and financial prospects. It highlights the introduction of a technology platform designed for personalized surgical procedures, particularly in bunion correction. While there are optimistic projections regarding synergies and growth opportunities, the company acknowledges inherent risks and uncertainties that may affect actual outcomes. The firm emphasizes a focus on improving surgical outcomes and educating both surgeons and patients.
Read more →TMCITreace Medical Concepts Reports First Quarter 2023 Financial Results PONTE VEDRA, Fla. –
Treace Medical Concepts reported a strong performance for Q1 2023, with revenue rising 45% year-over-year to $42.2 million. The company has improved patient outcomes as highlighted in the ALIGN3D clinical study, showcasing high satisfaction and low pain recurrence rates. However, it experienced an increase in net losses and operating expenses compared to the previous year. Despite these losses, Treace has raised its revenue guidance for the year, reflecting confidence in its growth strategy and expansion efforts.
Read more →TMCITreace Medical Concepts Reports Fourth Quarter and Full Year 2022 Financial Results PONTE VEDRA, Fla. –
Treace Medical Concepts reported strong financial results for Q4 2022 and full year 2022, with revenue increases of 49% for the quarter and 50% for the year. The company highlighted impressive patient satisfaction from its ALIGN3D clinical study data, showing a 97% satisfaction rate and notable surgical outcomes. Despite rising operating expenses and a significant net loss, Treace has a solid cash position and anticipates further revenue growth in 2023, driven by expanded market penetration and direct sales efforts.
Read more →TMCITreace Medical Concepts Provides 2022 Preliminary Unaudited Revenue
Treace Medical Concepts, Inc. announced preliminary unaudited revenue for the fourth quarter and full year 2022, projecting a revenue range of $49.1 to $49.6 million for Q4 and $141.2 to $141.7 million for the full year. This represents significant growth of 47% to 48% for Q4 and 50% for the entire year compared to the previous period. The company attributes this growth to strategic investments in direct sales, research and development, and direct-to-consumer initiatives. Future financial guidance for 2023 will be provided during an upcoming earnings call.
Read more →TMCITreace Medical Concepts Reports Third Quarter 2022 Financial Results PONTE VEDRA, Fla. –
Treace Medical Concepts Reports Third Quarter 2022 Financial Results PONTE VEDRA, Fla. November 8, 2022 Treace Medical Concepts, Inc. ( Treace or the Company ) (NasdaqGS: TMCI), a medical technology company driving a fundamental shift in the surgical treatment of hallux valgus (
Read more →TMCITreace Medical Concepts Appoints New Directors PONTE VEDRA, Fla. –
Treace Medical Concepts Appoints New Directors PONTE VEDRA, Fla. September 27, 2022 Treace Medical Concepts, Inc. ( Treace or the Company ) (NasdaqGS: TMCI), a medical technology company driving a fundamental shift in the surgical treatment of hallux valgus (commonly known as bu
Read more →TMCI▼ -5.8%on this news
Treace Medical Concepts Reports Second Quarter 2022 Financial Results PONTE VEDRA, Fla. –
Treace Medical Concepts Reports Second Quarter 2022 Financial Results PONTE VEDRA, Fla. August 9, 2022 Treace Medical Concepts, Inc. ( Treace or the Company ) (NasdaqGS: TMCI), a medical technology company driving a fundamental shift in the surgical treatment of hallux valgus (c
Read more →TMCI▼ -5.6%on this news· ran to -30% by day 3
Treace Medical Concepts Reports First Quarter 2022 Financial Results PONTE VEDRA, Fla. –
Treace Medical Concepts Reports First Quarter 2022 Financial Results PONTE VEDRA, Fla. May 5, 2022 Treace Medical Concepts, Inc. ( Treace or the Company ) (NasdaqGS: TMCI), a medical technology company driving a fundamental shift in the surgical treatment of hallux valgus (commo
Read more →TMCITreace Secures Up to $150 Million in Debt Financing
Treace Secures Up to $150 Million in Debt Financing PONTE VEDRA, Fla., May 2, 2022 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. ( Treace or the Company ) (Nasdaq: TMCI), a medical technology company driving a fundamental shift in the surgical treatment of hallux valgus (com
Read more →TMCITreace Medical Concepts Reports Fourth Quarter and Full Year 2021 Financial Results PONTE VEDRA, Fla. –
Treace Medical Concepts Reports Fourth Quarter and Full Year 2021 Financial Results PONTE VEDRA, Fla. March 3, 2022 Treace Medical Concepts, Inc. ( Treace or the Company ) (NasdaqGS: TMCI), a medical technology company driving a paradigm shift in the surgical treatment of hallux
Read more →TMCI▲ +14.9%on this news
Treace Medical Concepts Provides 2021 Preliminary Sales Results
Treace Medical Concepts Provides 2021 Preliminary Sales Results PONTE VEDRA, Fla. January 10, 2022 Treace Medical Concepts, Inc. ( Treace or the Company ) (NasdaqGS: TMCI), a commercial-stage orthopaedic medical device company driving a paradigm shift in the surgical treatment
Read more →TMCITreace Medical Concepts Reports Third Quarter 2021 Financial Results
Treace Medical Concepts Reports Third Quarter 2021 Financial Results PONTE VEDRA, Fla. - November 4, 2021-Treace Medical Concepts, Inc. ("Treace" or the "Company") (NasdaqGS: TMCI), a commercial-stage orthopaedic medical device company driving a paradigm shift in the surgical tr
Read more →TMCI▼ -5.4%on this news
Treace Medical Concepts Appoints New Directors
Treace Medical Concepts Appoints New Directors PONTE VEDRA, Fla. - October 4, 2021-Treace Medical Concepts, Inc. ("Treace" or the "Company") (NasdaqGS: TMCI), a commercial-stage orthopaedic medical device company driving a paradigm shift in the surgical treatment of Hallux Valgu
Read more →TMCITreace Medical Concepts Reports Second Quarter 2021 Financial Results
Treace Medical Concepts Reports Second Quarter 2021 Financial Results PONTE VEDRA, Fla. - August 5, 2021-Treace Medical Concepts, Inc. ("Treace" or the "Company") (NasdaqGS: TMCI), a commercial-stage orthopaedic medical device company driving a paradigm shift in the surgical tre
Read more →TMCITreace Medical Concepts Reports First Quarter 2021 Financial Results
Treace Medical Concepts Reports First Quarter 2021 Financial Results PONTE VEDRA, Fla. May 25, 2021 Treace Medical Concepts, Inc. ( Treace or the Company ) (NasdaqGS: TMCI), a commercial-stage orthopaedic medical device company driving a paradigm shift in the surgical treatment
Read more →Competitive Position
How TMCI ranks across every disease it competes inCompetitive Position is a premium feature
See how TMCI ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial